Barclays PLC Otonomy, Inc. Transaction History

Barclays PLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.72 - $2.51 $1,336 - $1,950	-777 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.72 - $2.47 $1,336 - $1,919	777 New	777 $2,000
Q4 2021 Feb 14, 2022	SELL	$1.69 - $2.31 $25,755 - $35,204	-15,240 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$1.22 - $2.2 $12,944 - $23,342	10,610 Added 229.16%	15,240 $29,000
Q2 2021 Aug 13, 2021	SELL	$2.06 - $2.67 $158,910 - $205,966	-77,141 Reduced 94.34%	4,630 $10,000
Q1 2021 May 13, 2021	BUY	$2.49 - $6.23 $129,838 - $324,857	52,144 Added 176.0%	81,771 $209,000
Q2 2020 Aug 12, 2020	SELL	$1.87 - $3.84 $7 - $15	-4 Reduced 0.01%	29,627 $107,000
Q1 2020 May 13, 2020	SELL	$1.58 - $4.06 $2,535 - $6,516	-1,605 Reduced 5.14%	29,631 $58,000
Q4 2019 Feb 10, 2020	SELL	$2.13 - $3.83 $48 - $88	-23 Reduced 0.07%	31,236 $120,000
Q2 2019 Aug 14, 2019	SELL	$2.35 - $3.09 $218 - $287	-93 Reduced 0.3%	31,259 $86,000
Q1 2019 May 15, 2019	BUY	$1.8 - $2.97 $16,263 - $26,833	9,035 Added 40.48%	31,352 $82,000
Q4 2018 Feb 14, 2019	SELL	$1.51 - $2.93 $122,785 - $238,252	-81,315 Reduced 78.47%	22,317 $41,000
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.95 $111,092 - $168,775	-42,728 Reduced 29.19%	103,632 $284,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $4.75 $7,329 - $9,409	1,981 Added 1.37%	146,360 $564,000
Q1 2018 May 15, 2018	SELL	$4.05 - $6.1 $6,176 - $9,302	-1,525 Reduced 1.05%	144,379 $606,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $5.55 $379,414 - $752,052	135,505 Added 1303.06%	145,904 $809,000
Q3 2017 Nov 14, 2017	BUY	$3.2 - $20.8 $33,276 - $216,299	10,399	10,399 $34,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.